Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Metal & realty out of favour
Tue, 15 Apr 01:30 pm

Indian share markets continued to witness selling pressure in the post-noon trading session. Barring IT, all the sectoral indices are trading in the red with metal, realty and banking stocks being the biggest losers.

BSE-Sensex is down 185 points and NSE-Nifty is trading 63 points down. BSE Mid Cap is trading 0.4% down and BSE Small Cap index is trading down by 0.3%. The rupee is trading at 60.3 to the US dollar.

Steel stocks are trading mixed with Maharashtra Seamless and Adhunik Metaliks being the major gainers whereas Jindal Steel and SAIL are among the biggest losers. As per a leading financial daily, India turned into a net steel exporter in FY14 after a gap of five years. According to the Joint Plant Committee, steel exports increased by 4% to 5.6 million tonnes (mt) whereas steel imports slumped by 31% to 5.4 mt in 2013-14. Going forward, steel exports are likely to be hit by the recent rupee appreciation as well as the expected recovery in the infrastructure projects in the country post elections that is likely to boost domestic steel demand. Domestic steel consumption in FY14 clocked a growth of a mere 0.6%, the slowest in last four years, to reach 73.9 mt. However JSW Steel has said that despite improvement in domestic demand, steel companies will continue to focus on exports backed by higher production and no currency fluctuations.

Majority of the domestic pharma stocks are trading in the green with Panacea Biotech and Biocon being among major gainers. However, Elder Pharma and Divi's Laboratories are a few stocks trading in the red. As per a leading financial daily, Lupin has voluntarily recalled 9,210 bottles of antibiotic drug Suprax used in the treatment of bacterial infections. As per US Food and Drug Administration (USFDA), the recall has been initiated under Class III under which the drugs are not likely to cause adverse health consequences. Last year, Lupin had recalled 64,368 bottles of Suprax in the US market due to discolouration. According to the company, the present recall will not have any business consequence. Lupin stock is presently trading down marginally.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Metal & realty out of favour". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.